Patents by Inventor Michael A. Innis

Michael A. Innis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5795779
    Abstract: .beta.-interferon is produced in Chinese hamster ovary cells (CHO) in high amounts.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: August 18, 1998
    Assignees: Berlex Laboratories, Inc., Leland Stanford Junior University
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 5696088
    Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: December 9, 1997
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Abla A. Creasey
  • Patent number: 5589359
    Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: December 31, 1996
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Abla A. Creasey
  • Patent number: 5563123
    Abstract: Chimeric proteins possessing Kunitz-type domain 1 of TFPI-2 and Kunitz-type domain 2 of TFPI are disclosed, as are muteins of TFPI and TFPI-2. Nucleic acid sequences, expression vectors and transformed host cells encoding and capable of producing the disclosed chimeric proteins and muteins are also disclosed. Finally, methods for prevention and treatment of septic shock using the chimeric proteins and muteins are disclosed.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: October 8, 1996
    Assignee: Chiron Corporation
    Inventors: Michael A. Innis, Abla A. Creasey
  • Patent number: 5376567
    Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host, IFN, either constitutive or inductive.
    Type: Grant
    Filed: January 9, 1992
    Date of Patent: December 27, 1994
    Assignees: Berlex Laboratories, Inc., Board of Trustees of the Leland Stanford, Jr. Univ.
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 5142033
    Abstract: Structure-independent amplification of DNA by the polymerase chain reaction can be achieved by incorporation of 7-deaza-2'-deoxyguanosine-5'-triphosphate into the amplified DNA.
    Type: Grant
    Filed: July 31, 1991
    Date of Patent: August 25, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Michael A. Innis
  • Patent number: 5098703
    Abstract: A new polypeptide, called IFN-.alpha.76, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: March 24, 1992
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 5091310
    Abstract: Structure-independent amplification of DNA by the polymerase chain reaction can be achieved by incorporation of 7-deaza-2'-deoxyguanosine-5'-triphosphate into the amplified DNA.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: February 25, 1992
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 5075216
    Abstract: Dideoxynucleotide DNA sequencing methods can be dramatically improved by utilizing the DNA polymerase from Thermus aquaticus to catalyze the primer extension reactions.
    Type: Grant
    Filed: September 23, 1988
    Date of Patent: December 24, 1991
    Assignee: Cetus Corporation
    Inventors: Michael A. Innis, Kenneth B. Myambo, David H. Gelfand, Mary Ann D. Brow
  • Patent number: 5045463
    Abstract: A gene having a DNA sequence complementary to that of the glucoamylase polypeptide mRNA from a fungal species, preferably Aspergillus awamori, is prepared. The mRNA is an approximately 2.2 kilobase poly A RNA obtained from fungal cells grown under conditions of glucoamylase induction. Reverse transcription of the mRNA provides a glucoamylase probe used to identify genomic digest fragments containing glucoamylase gene regions, which are sequenced to locate the introns and exons. The genomic fragments are spliced together to form a gene having a DNA sequence with altered or deleted introns which codes for fungal glucoamylase protein and is capable, when correctly combined with a cleaved DNA expression vector, of expressing a non-native protein having glucoamylase enzyme activity upon transformation of a host organism by the vector. The host is preferably bacteria or yeast. The transformed yeast host may be used to produce ethanol.
    Type: Grant
    Filed: December 19, 1988
    Date of Patent: September 3, 1991
    Assignee: Cetus Corporation
    Inventors: Michael A. Innis, David H. Gelfand, James H. Meade
  • Patent number: 4975276
    Abstract: A new polypeptide, called IFN-.alpha.54, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: December 4, 1990
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 4973479
    Abstract: A new polypeptide, called IFN-.alpha.61, produced by E. coli transformed with a newly isolated and characterized human IFN-.alpha. gene is described. The polypeptide exhibits interferon activities such as antiviral activity, cell growth regulation, and regulation of production of cell-produced substances.
    Type: Grant
    Filed: September 2, 1982
    Date of Patent: November 27, 1990
    Assignee: Cetus Corporation
    Inventor: Michael A. Innis
  • Patent number: 4966843
    Abstract: DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The human recombinant interferon so produced contains glycans which are a subset of the population of glycans which are contained in the native counterpart, and may be used in therapeutic formulations. The CHO cells yield high levels of human interferon with no detectable amounts of host IFN, either constitutive or inductive.
    Type: Grant
    Filed: July 31, 1985
    Date of Patent: October 30, 1990
    Assignee: Cetus Corporation
    Inventors: Francis P. McCormick, Michael A. Innis, Gordon M. Ringold
  • Patent number: 4794175
    Abstract: A gene having a DNA sequence complementary to that of the glucoamylase polypeptide mRNA from a fungal species, preferably Aspergillus awamori, is prepared. The mRNA is an approximately 2.2 kilobase poly A RNA obtained from fungal cells grown under conditions of glucoamylase induction. Reverse transcription of the mRNA provides a glucoamylase probe used to identify genomic digest fragments containing glucoamylase gene regions, which are sequenced to locate the introns and exons. The genomic fragments are spliced together to form a gene having a DNA sequence with altered or deleted introns which codes for fungal glucoamylase protein and is capable, when correctly combined with a cleaved DNA expression vector, of expressing a non-native protein having glucoamylase enzyme activity upon transformation of a host organism by the vector. The host is preferably bacteria or yeast. The transformed yeast host may be used to produce ethanol.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: December 27, 1988
    Assignee: Cetus Corporation
    Inventors: Jack Nunberg, Jeffrey E. Flatgaard, Michael A. Innis
  • Patent number: 4752585
    Abstract: A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine T or peroxide oxidation, wherein additional, non-susceptible methionyl residues are not so substituted. The oxidation-resistant mutein so produced is preferably a human mutein of interleukin-2 or interferon-.beta., and the conservative amino acid is most preferably alanine.
    Type: Grant
    Filed: August 5, 1986
    Date of Patent: June 21, 1988
    Assignee: Cetus Corporation
    Inventors: Kirston E. Koths, Robert F. Halenbeck, Michael A. Innis, Alice M. Wang, Ze'Ev Shaked